

LYMPHOID NEOPLASIA

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in *CRBN* and Ras pathway genes

K. Martin Kortüm,^{1,2,*} Elias K. Mai,^{3,4,*} Nur H. Hanafiah,^{3,*} Chang-Xi Shi,¹ Yuan-Xiao Zhu,¹ Laura Bruins,¹ Santiago Barrio,¹ Patrick Jedlowski,¹ Maximilian Merz,⁴ Jing Xu,^{3,5} Robert A. Stewart,¹ Mindaugas Andriulis,⁵ Anna Jauch,⁶ Jens Hillengass,⁴ Hartmut Goldschmidt,^{4,7} P. Leif Bergsagel,¹ Esteban Braggio,¹ A. Keith Stewart,^{1,8} and Marc S. Raab^{3,4}

¹Department of Hematology, Mayo Clinic in Arizona, Scottsdale, AZ; ²Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany; ³Max-Eder Group "Experimental Therapies for Hematologic Malignancies," Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; ⁴Department of Internal Medicine V, and ⁵Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; ⁶Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; ⁷National Center of Tumor Diseases, Heidelberg, Germany; and ⁸Center for Individualized Medicine, Mayo Clinic, Rochester, MN

Key Points

- The incidence of mutations within the MAPK pathway, the *CRBN* pathway, and *TP53* is significantly increased in drug-refractory MM.
- Mutations in *CRBN* might contribute to IMiD resistance in drug-refractory MM.

In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation Panel. Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), and 88%, 78%, and 68% were refractory to an IMiD, a PI, or both, respectively. The majority of patients had progressive (82%) or refractory (78%) disease immediately before sampling, with 43% being IMiD refractory and 46% being PI refractory in the most recent line of therapy. Compared with newly diagnosed MM, an increased prevalence of mutations in the Ras pathway genes *KRAS*, *NRAS*, and/or *BRAF* (72%), as well as *TP53* (26%), *CRBN* (12%), and *CRBN* pathway genes (10%) was observed. Longitudinal analyses performed in 3 patients with *CRBN* mutations at time of IMiD resistance confirmed that these mutations were undetectable at earlier, IMiD-sensitive time points. Furthermore, the functional introduction of these mutations in MM cells conferred lenalidomide resistance *in vitro*. These data indicate a differential genetic landscape in rMM associated with drug response. (*Blood*. 2016;128(9):1226-1233)

Introduction

Significant efforts have recently been made to better understand the genetic landscape of multiple myeloma (MM), with more than 1000 MM exomes sequenced to date.¹⁻⁵ However, most of the data have been obtained from untreated or heterogeneously treated cohorts. Recurrent mutations have been identified only in a limited number of genes, a subset of which seems to affect survival.^{1,6,7} Patterns of clonal evolution were identified; however, these findings are still based on a relatively small number of intensively longitudinally studied patients.^{2,8-10}

Although the novel agents, namely immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) paved the road toward a prolonged survival and durable responses, most MM patients eventually relapse and become drug refractory. The mechanisms underlying resistance to IMiDs, PIs, and corticosteroids, however, remain poorly understood. Cereblon (*CRBN*) was recently identified as being essential for the anti-MM activity of IMiDs.¹¹⁻¹⁸ To date, the reported incidence of mutations in proteasome subunits, the *CRBN* pathway, or the steroid receptor is low, and mutations in these genes, except in single case studies^{19,20} or *in vitro* cell line analyses,^{20,21} have not yet been identified as a major source of primary or acquired drug resistance in larger MM data sets.

The acquisition or the selection of mutants under the selective pressure of targeted therapy has been shown to be a key driver of the

development of drug resistance in other hematologic malignancies (eg, BCR-ABL mutations in imatinib-treated chronic myeloid leukemia²² or *BTK* mutations in chronic lymphocytic leukemia patients treated with the selective inhibitor ibrutinib).²³ Of note, genomic data from large series of homogeneously pretreated patients with refractory MM (rMM) are still missing.

Therefore, in this study, 88 frequently mutated or drug-resistance pathway MM genes with a focus on genes relevant to IMiD and PI interactions were investigated in a cohort of 50 heavily pretreated rMM patients by using our updated disease-specific Multiple Myeloma Mutation Panel (M³P v3.0). Our approach yielded rapid, robust, and sensitive variant screening and allowed for the detection of small subclonal mutations. Strikingly, we were able to identify mutations in potentially targetable genes and in genes related to drug resistance in the majority of patients.

Patients and methods

Patients

Between November 2013 and April 2015, samples from 50 rMM patients were collected at the University Hospital Heidelberg (Heidelberg, Germany). Samples

Submitted February 5, 2016; accepted June 28, 2016. Prepublished online as *Blood* First Edition paper, July 25, 2016; DOI 10.1182/blood-2016-02-698092.

*K.M.K., E.K.M., and N.H.H. contributed equally to this study.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2016 by The American Society of Hematology

were obtained from bone marrow aspirates in 44 of the patients. In 6 patients with extramedullary disease, tumor DNA was obtained from tissue block (n = 2; patients #1 and #7) and from peripheral blood (n = 4; secondary plasma cell leukemia; #2, #3, #16, and #17). In all but one patient (#30), the corresponding germ line was available for analysis, and in 3 patients with acquired IMiD resistance at tumor sampling (#12, #24, and #32), prior samples from earlier IMiD-sensitive disease were available for comparative analysis. Patients in our study had received a minimum of 2 previous lines of therapy and had been exposed to at least one PI and one IMiD. All patients gave written informed consent to the sampling, analysis of tumor and germ line probes, and collection of clinical data in accordance with the Declaration of Helsinki. Data collection and analysis were approved by the institutional ethics committee (Heidelberg #229/2003, S-152/2010).

Collection of clinical data

Clinical data were collected retrospectively from internal digital and external paper patient records. Refractory disease was defined according to International Myeloma Working Group criteria²⁴ as either progressive disease (PD) under therapy or within 60 days after discontinuation of therapy.

Sample preparation

Mononuclear cells were isolated by density centrifugation (Biocoll Separating Solution; Biochrom GmbH, Berlin, Germany). Magnetic cell separation of CD138⁺ and CD138⁻ subsets from the mononuclear cells was performed by using Microbeads CD138-Human and Manual MACS Cell Separation Units (Miltenyi Biotec, Bergisch Gladbach, Germany). Sample purity was assessed by flow cytometry to be >85%. The CD138⁻ subsets were further cultured to obtain the stroma cells. Sample purity of stroma cells was assessed by flow cytometry to contain <1% CD138⁺ cells. Sample purity of tissue blocks was estimated by the infiltration rate of clonal plasma cells assessed by immunohistochemistry for CD138. DNA from isolated cells was extracted by using the QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany). DNA extraction from tissue blocks was performed at the Institute of Pathology (Heidelberg, Germany) as previously described.²⁵ Germ line controls for sequencing studies were obtained from stroma cells, as described above, or from buccal swabs, which were processed by using the blackPREP Swab DNA Kit (Analytikjena; Biometra, Berlin, Germany) and stored at -20°C.

Targeted sequencing

Targeted sequencing was performed on the personal genome machine (ThermoFisher, Waltham, MA) by using 20 ng DNA from flow-sorted CD138⁺ plasma cells as well as from corresponding germ line samples. IonOneTouch automated systems were used to generate and enrich 400 bp libraries. Our 185-kb customized M³P v3.0 includes 1327 amplicons covering the coding regions of 88 disease-specific genes (supplemental Table 1, available on the *Blood* Web site). We selected key genes in pathways previously identified as being important in MM (MAPK, nuclear factor κB, interleukin-6, cell cycle, MYC) as well as genes known to be expressed in MM and being recurrently mutated in >2% of patients in previously published genome-wide MM studies. Furthermore, we selected genes that provide a potential drug target and genes that have been associated with drug resistance to the most commonly used drug families (IMiDs, PIs, and corticosteroids). Three paired tumor and germ line samples were barcoded by using the Ion Xpress Barcode Adapters, pooled, and sequenced on a 318TM chip by using the Ion PGM Hi-Q Seq Kit (Thermo-Fisher). An average of ~800× depth sequencing coverage was generated per nucleotide. Mutation analysis was performed by using Ion Reporter Software v4.4 (Thermo-Fisher), and further data curation was performed by using the Biological Reference Repository (BioR, Mayo Clinic, Rochester, MN).²⁶ BioR includes gene annotations that use various database resources, including National Center for Biotechnology Information/Ensembl; University of California, Santa Cruz (UCSC); Single Nucleotide Polymorphism Database (dbSNP); HapMap; 1000 Genomes Project; the Catalogue of Somatic Mutations in Cancer (COSMIC; Wellcome Trust Sanger Institute); SIFT (J. Craig Venter Institute)²⁷; and PolyPhen-2 (Harvard Medical School).²⁸ Germ line variants were filtered out by comparing each tumor sample with its germ line counterpart. We then filtered synonymous variants and variants identified outside exonic and splicing site

regions and visualized the remaining calls by using the Integrative Genomics Viewer (Broad Institute, Cambridge, MA). Finally, we eliminated from further analyses the variants that were either supported with unidirectional reads, covered with <20× depth, or found in <3% of reads in the tumor sample. For the sample for which we had no germ line sample available, we applied the same filters; however, we included only those findings that were listed in the COSMIC database and excluded those that were present in dbSNP or in 1000 Genomes Project with a prevalence of more than 1%.

For the comparative analysis of longitudinal samples, we used a specific 400 bp gene panel containing a reduced number of 24 amplicons including *CRBN* and batched 3 CD183 tumor samples on a 318 chip. This allowed us to ensure the maximum sensitivity of the personal genome machine technology (~10⁻³). All sequencing data are deposited in the Sequence Read Archive database (<http://www.ncbi.nlm.nih.gov/sra>); study accession number is SRP066263.

Site-directed mutagenesis for functional *CRBN* mutation analysis

To establish mutant *CRBN*-expressing OCI-MY5 cell lines, we created lentivector pCDHPuroCRBN by subcloning wild-type (wt) CRBN from pCDHGFPCRBN and used this pCDHPuroCRBN as a template to introduce CRBN mutations by polymerase chain reaction (see supplemental Data for details). The ligated plasmid was amplified and isolated by using a Miniprep Plasmid Isolating Kit (QIAGEN) and then cloned into lentivector pCDH-CMV-MCS-EF1-Puro (SBI, Mountain View, CA) and packaged into a lentivirus. The lentivirus constructs were then used to infect OCI-MY5 myeloma cells to overexpress mutant CRBN protein. Cell viability was assessed in triplicate by using 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) after a 5-day incubation time with increasing doses of lenalidomide.

Results

Patient characteristics and previous therapies

Baseline characteristics of the patient cohort are described in Table 1. Cytogenetic results were available in 39 patients (78%) and included gain 1q21 (>2 copies), deletion 17p, and translocations t(4;14) and t(14;16) in 62%, 33%, 13%, and 8% of screened patients. Overall, 82% of patients carried at least 1 adverse cytogenetic aberration (Figure 1). Patients received a median of 5 prior therapies before tumor sampling (range, 2 to 15 prior therapies). All patients were exposed to at least 1 IMiD and 1 PI, and 88%, 78%, and 68% of patients were refractory to at least 1 IMiD, PI, or PI/IMiD, respectively. At time of sampling, 82% of patients had PD and 78% were refractory to the last line of treatment. The median time between PD and sampling was 12 days (range, 0 to 164 days). Previous therapies and refractory status immediately before sampling are described in Table 1 and displayed in Figure 1.

Detected mutations with M³P

In our cohort of 50 patients, we detected 136 mutations, resulting in an average mutation incidence of 2.7 per patient (range, 0 to 13 mutations), of which there were 114 missense (84%), 9 nonsense (7%), 1 stop lost (1%), 11 frameshift deletions (8%), and 1 frameshift insertion (1%), and 6 were located in splice donor or acceptor sites (4%). We found mutations in at least 1 of the selected M³P genes in 98% of patients, and at least 1 mutation was identified in 47 (53%) of the 88 investigated genes (Figure 1). Multiple mutations within the same gene were observed in 5 patients, 1 of whom harbored 4 mutations within the steroid receptor *NR3C1* (variant reads [VRs], 7% to 17%). Other genes harboring multiple mutations in a single patient included *BRAF* (VRs, 54%/41%), *CUL4B* (VRs, 19%/6% and 5%/5%), *NFKB2* (VRs, 26%/6%), and *TP53* (VRs, 18%/8% and 14%/8%) (supplemental Table 2). PolyPhen-2,²⁹ SIFT,²⁷ and PROVEAN³⁰ were applied to estimate the

Table 1. Baseline patient characteristics and previous treatments

Characteristic	No.	%
Baseline	(n = 50)	
Sex		
Male		52
Female		48
Age, years		
Median at diagnosis (range)	58.8 (38.1-73.5)	
Median at sampling (range)	65.5 (44.7-85.3)	
Median time from initial treatment to sampling, years (range)	4.8 (1.4-13.8)	
Heavy chain		
IgG		60
IgA		22
Light chain disease		18
Light chain		
κ		66
λ		34
Median hemoglobin, g/dL (range)	10.6 (7.0-14.6)	
Median No. of thrombocytes per microliter (range)	104.0 (15.0-302.0)	
Median LDH, U/L (range)	230.5 (124.0-2294.0)	
Median GFR, mL/min (range)	69.4 (8.0-148.0)	
Salmon and Durie stage at diagnosis		
IIA		6
IIB		0
IIIA		78
IIIB		16
Cytogenetic analyses performed		78
Cytogenetic aberrations	(n = 39)	
Gain 1q21 (>2 copies)		62
Deletion 17p		33
t(4;14)		13
t(14;16)		8
At previous treatments	(n = 50)	
Median No. of previous lines of therapy (range)	5 (2-15)	
Prior exposure class		
PI		100
IMiD		100
Cytotoxic agent		94
HDT		90
Prior exposure agent		
Bortezomib		100
Carfilzomib		18
Thalidomide		34
Lenalidomide		100
Pomalidomide		48
Refractory class		
PI		76
IMiD		88
PI + IMiD		66
Refractory agent		
Bortezomib		72
Carfilzomib		16
Thalidomide		14
Lenalidomide		82
Pomalidomide		40
PD prior to sampling		82
Refractory to last therapy		78
Refractory to last therapy agent	(n = 39)	
Bortezomib		33
Carfilzomib		13
Lenalidomide		20
Pomalidomide		23
Bendamustine		8
Monoclonal CD38 antibody		3

Laboratory values at the time of sampling are shown. GFR, glomerular filtration rate; HDT, high-dose therapy; IgG, immunoglobulin G; LDH, lactate dehydrogenase; PD, progressive disease.

functional impact of each mutation. In total, predictions for 115 mutations were generated and in 93% of cases a damaging, potentially damaging, or probably damaging impact was assessed by at least 1 of the algorithms. The mutational spectrum observed was broad, with a significant number of small subclonal mutations; VRs did not reach 10% in more than a quarter (26%) of all mutations, and almost half (45%) of the mutations identified were below a VR of 25% (supplemental Table 2).

Ras pathway—*KRAS/NRAS/BRAF*

The incidence of mutations in the RAS pathway in our refractory cohort was quite high, with 36 patients (72%) having at least 1 mutation in *NRAS*, *KRAS*, and/or *BRAF*, significantly exceeding previously published frequencies in newly diagnosed patients (Figure 1).¹⁻⁴ We observed 9 *BRAF*-mutated patients (18%), with 4 (8%) having the mutation at known activating and druggable site p.Val600Glu.^{31,32} In 4 patients, kinase-inhibiting *BRAF* mutations were identified, known to paradoxically activate the MAPK pathway via c-RAF (Gly466Val,³³ Gly469Arg,³⁴ and Asp594Asn³⁵ [present in 2 patients]). Two patients showed additional activating mutations in *NRAS* and *KRAS*, respectively, and 1 patient harbored 2 *BRAF* mutations (Lys499Asn and Glu695Lys) (supplemental Table 2). Finally, 2 patients (4%) with *RASA2* mutations and 1 patient with an activating mutation in *PTPN11* were identified; both of the genes had potentially activating effects on the MAPK pathway.^{36,37}

TP53

We saw an increased incidence of *TP53* mutations in our patient cohort (26%), more commonly found in patients with del17p (8 [62%] of 13) compared with patients without the deletion (4 [15%] of 26) (Figure 1). Two patients harbored 2 mutations within the gene. The majority of mutations were found within subclonal ranges (9 of 15 mutations: 16% VRs or less; supplemental Table 2).

CRBN-associated mutations

Of note, the cereblon pathway, important for the anti-MM action of IMiDs,^{12-14,17} was found mutated in almost one-quarter of patients (22%). This includes *CRBN* (12%), *CUL4B* (6%), *IRF4* (4%), and *IKZF1* (2%) (Figure 1; supplemental Figure 1). All *CRBN* mutations found in our cohort were detected in patients with IMiD-refractory disease (patients #5, #12, #24, #32, #34, and #38; Figure 1) as was the case for mutant *CUL4B* (#6, #15, and #38) and *IKZF1* (#2). The mutation found in *IKZF1* (p.Ala152Thr) is located inside a sequence of 30 amino acids known from a previous study to be essential for lenalidomide sensitivity.¹⁷ All *CRBN* mutations occurred at critical sites, potentially having an impact on *CRBN*-IMiD interactions by either truncating the protein (p.Ile393Metfs*10 [#5], p.Pro241Argfs*10 [#38], p.Gln327* [#12], and splicing acceptor c.551-2T>C [#34]; supplemental Table 2) or by being located within the thalidomide-binding domain (p.Phe381Cys [#24] and p.Pro411His [#32]) as illustrated in Figure 2.^{38,39}

Furthermore, the cumulative time on IMiD treatment among the 6 *CRBN*-mutant patients (median, 1146 days; range, 154 to 1912 days) was longer compared with *CRBN* wt patients (median, 479 days; range, 40 to 2182 days; *P* = .02).

In 3 *CRBN*-mutated patients with acquired resistance to IMiDs (#12, #24, and #32), earlier tumor samples collected before refractory lenalidomide or pomalidomide treatment were available (Figure 3; supplemental Figure 2). In all 3 patients, the mutation was undetectable at the earlier time point, even with an increased sequencing depth.




Figure 1. Genomic mutations, adverse cytogenetic aberrations, and treatment characteristics of 50 relapsed/refractory MM patients. All patients are identified by individual numbers. Refractory status to IMiDs or PIs at any time before sampling is shown as well as PD and refractory (IMiD, PI, other drug classes) status immediately before sampling. Information on the adverse cytogenetic aberrations gain 1q21 (>2 copies), deletion (17p), and translocations t(4;14) and t(14;16) are depicted. Genes mutated in at least 1 patient are displayed. Genes (from top to bottom) and patients (from left to right) are sorted according to gene mutation frequencies. Treatment characteristics and cytogenetic aberrations are color-coded: red, yes; green, no; gray, unknown/not available. Refractory drugs immediately prior to sampling are also color-coded: purple, IMiD refractory; blue, PI refractory; orange, other drug classes (including cytotoxic agents and antibodies); green, not refractory to treatment immediately prior to sampling.

To assess the impact of these 3 *CRBN* mutations on protein function and sensitivity to IMiD treatment, the mutations were introduced into the myeloma cell line OCI-MY5. OCI-MY5 is characterized by a very low expression of wt *CRBN*, rendering the cell line IMiD resistant. When wt *CRBN* is introduced and overexpressed, OCI-MY5 regains IMiD sensitivity.¹² We introduced and overexpressed all 3 *CRBN* mutations into OCI-MY5 in independent experiments, as well as the wt *CRBN* (positive control) and the viral vector alone (negative control). Cell viability was assessed by using an MTT assay (in triplicate) after a 6-day treatment with increasing doses of lenalidomide (Figure 4). The OCI-MY5 wt cells regained lenalidomide sensitivity, whereas the OCI-MY5 cells containing the *CRBN* mutants or the viral vector alone remained lenalidomide resistant. The expression of exogenous wt and mutated *CRBN* was detected by an immunoblotting assay using an anti-*CRBN* antibody.

PI resistance-associated mutations

Only limited data are currently available regarding mutations in proteasomal subunits associated with resistance to PI-based therapies in MM. Thus, only a limited number of genes coding for proteasomal subunits were selected for our current M³P design (supplemental Table 1). Mutations of *XBPI* or PI subunits (*PSMB8* and *PSMD1*) were found in 2 patients (4%) in our cohort, with 1 plasma cell leukemia patient carrying a mutation in both *PSMB8* and *PSMD1*. The response of the latter patient to PIs was unavailable. However, another patient with a p.L314Ffs*38 *XBPI* had known PI resistance at the time of tumor sampling.

Other genes with potential therapeutic implications

Besides *BRAF*, other mutations in potentially actionable genes were identified in a subset of patients, including *IDH1/2*, and *FGFR3* (Figure 1). IDH mutations are frequently found in glioma⁴⁰ or acute




Figure 2. Localization of mutations within the *CRBN* gene. *CRBN* mutations were found in 6 patients. All mutations found in our cohort occurred at critical sites, and they had the potential to impact *CRBN*-IMiD interactions by truncating, affecting splicing, or being located within the IMiD-binding site of *CRBN*. Each mutation is described at the corresponding site of the *CRBN* protein. *CRBN*, cereblon; LON, long undivided filaments upon ultraviolet irradiation (homo-oligomeric ATP-dependent protease domain).

myeloid leukemia.⁴¹ An *IDH1*-activating mutation at amino acid position 132 (p.Arg132His) found in 1 patient provides a druggable target, provided that it is of functional relevance in MM, and specific inhibitors for activating *IDH1* mutations are in advanced clinical testing.^{42,43} *FGFR3* has been identified as a druggable target, and we identified an activating p.Arg248Cys mutation^{44,45} and an activating read-through stop lost mutation *809Cys⁴⁶ in our cohort. Various specific *FGFR3*-inhibiting agents are in clinical and preclinical investigation in MM. The most promising results have been obtained in solid tumors.^{47,48} Furthermore, 1 *FGFR3* mutation is present in a t(4;14) patient (#49), whereas the translocation status is unknown in the second patient (#40). However, whether the sequelae conferred by the translocation in general or whether specific *FGFR3* mutations are essential for successful anti-*FGFR3* treatment remains to be confirmed.

Discussion

Despite the fact that more than 1000 MM genomes have already been sequenced, the mutational landscape of drug-refractory MM remains largely unknown, and our understanding of drug resistance mechanisms to the most commonly used drug families is limited. We have therefore designed and established a disease-specific MM gene panel (M³P) for rapid and sensitive variant screening in key MM genes. Our panel includes a subset of disease-specific key MM genes that we used to screen a selected cohort of 50 drug-refractory MM patients. We provide evidence that M³P sequencing can generate valuable information within potentially meaningful timeframes for clinical decision-making in the vast majority of rMM patients.

Mutations in potentially targetable genes (*MAPK*, *FGFR3*, and *IDH1*) were detectable in 76% of patients, whereas mutations in genes affecting the prognosis as described in previous studies of newly diagnosed MM (*TP53*, *EGRI*, and *IRF4*)¹ were identified in 32% of patients. Mutations in genes potentially associated with drug response (*CRBN* pathway, *XBPI*, proteasome subunits) were identified in 24% of patients.

MAPK mutations provide a broad potential target for advanced MM patients. *BRAF* or *MEK* inhibitors are already in clinical testing and seem promising.^{31,32,49,50} *NRAS* and *KRAS* mutations occurred mostly within known activating hotspots of the gene, and 4 of 9 *BRAF* mutations were druggable p.Val600Glu. However, *BRAF* mutations with paradoxical activation of the pathway via c-raf were also found in 4 patients, and in 1 of them (patient #41), 2 simultaneous *BRAF* mutations were identified:

1 at amino acid position 499 that has been suggested to be ERK activating and has been described in cardiofaciocutaneous syndrome,⁵¹ and 1 in p.Glu695Lys, located in the protein kinase domain within the activator loop, previously reported in skin cutaneous melanoma.⁵² In addition, a Gly503Arg mutation in *PTPN11*, another gene of the RAS pathway that has been reported as being frequently mutated in RAS-opathies (juvenile myelomonocytic leukemia, adult acute myelogenous leukemia, gastric cancer, glioblastoma, and anaplastic large cell lymphoma) was identified.^{36,37,53} This gene is thought to play a role in acquired resistance to targeted therapy⁵⁴ and therefore represents a potential drug target. *PTPN11*/*SHP2* inhibitors have already been identified, and compounds are in preclinical testing.⁵⁵ Furthermore, *RASA2* was found to be mutated in 2 patients. Mutations in this gene have been described in various malignancies, including colorectal, skin, lung, and endometrial cancers; however, the biological function of the gene has not yet been fully deciphered, and it is hypothesized to be a RAS inhibitor.⁵⁶ Of note, 1 of the patients (#1) with a Val600Glu *BRAF* mutation harbored an additional nonsense mutation in *RASA2*, which may contribute to further *MAPK* activation in this patient.

The most remarkable finding of our study is the identification of direct mutations in *CRBN* in 12% of patients and mutations in the *CRBN* pathway in almost one-quarter (22%) of the cohort. Although a role of mutant *IRF4* in IMiD resistance remains to be established, *CRBN* is the central mediator of IMiD action, and its expression is essential for the anti-MM effects of IMiDs.¹²⁻¹⁶ Notably, all *CRBN*-mutated patients (n = 6) and 10 (91%) of 11 of the *CRBN* pathway-mutated patients were unresponsive to IMiD-based treatment at the time of tumor sampling (the IMiD-refractory status of 1 patient was unknown) suggesting an association of these mutations with IMiD response. Thus far, *CRBN* mutations are largely absent in the publicly available MM sequencing data that, of note, include mostly untreated patients. For example, within 511 of the most recently analyzed patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpass trial, only 1 *CRBN* mutation (p.Pro85Ser) was identified (<https://research.themmrf.org/>). Similarly, in 349 untreated M³P-sequenced patients at the Mayo Clinic, we identified only 1 *CRBN* mutation (p.Asn316Lys) located in close proximity to the IMiD-binding site of the gene. Of interest, this patient did not respond to either lenalidomide induction or subsequent pomalidomide treatment, suggesting a potential impact of that mutation on the patient's IMiD response. Although primary and secondary resistance to IMiDs is observed in MM patients, mutations in this gene or pathway as the underlying cause for IMiD resistance have not yet been described in the disease apart from a single case report of a highly




Figure 3. Clinical course and treatment history of 3 MM patients with acquired IMiD resistance. CD138-purified tumor samples were obtained after progression to an IMiD-based treatment and from earlier IMiD-responsive disease stages in each patient. A mutation in *CRBN* was identified at IMiD-resistant disease stage (black circles). This mutation, however, was undetectable at earlier IMiD-sensitive disease stages in all 3 patients (white circles), suggesting a correlation with the acquired IMiD resistance in these patients. Patient #12 (*CRBN* mutation Q327TER) was a 72-year-old female diagnosed with MM immunoglobulin G kappa (IgG κ). She was initially treated with bortezomib (BTZ), rapidly relapsed, and died as a result of PD during lenalidomide (LEN) treatment (detection of *CRBN* mutation). Patient #32 (*CRBN* mutation P411H) was a 44-year-old female diagnosed with MM IgG κ. She was treated with several chemotherapy agents, high-dose melphalan (HDM), and novel agents, including BTZ, carfilzomib (CFZ), LEN, and pomalidomide (POM), and she died during PD from POM-refractory disease (detection of *CRBN* mutation). Patient #24 (*CRBN* mutation F381C) was a 64-year-old male diagnosed with MM IgA λ. Initial treatments included tandem (tand.) HDM and interferon (IFN) maintenance. After a long disease course with several short retreatments including BTZ, LEN, and HDM, the disease became lenalidomide-refractory (detection of *CRBN* mutation) and conventional chemotherapy was begun. Black arrows indicate refractoriness to the indicated treatment. CTX, chemotherapy; mt., maintenance; RIC-allo, reduced-intensity conditioning allogeneic stem cell transplantation; Thal, thalidomide.

drug-resistant patient.¹⁹ The increased incidence of *CRBN* and *CRBN* pathway-associated mutations in our cohort might be explained by cohort selection. In addition, the targeted sequencing approach allowed us to screen with increased sensitivity for variants and, in fact, 3 of the 6 *CRBN* mutations in our cohort were identified with VRs below 10% of the reads. In these 3 patients with subclonal *CRBN* mutations, we had earlier tumor samples available. All 3 patients had responded to IMiD treatment after earlier sampling (Figure 3) and even with increased sequencing sensitivity, we were unable to detect any *CRBN* mutations in the earlier, IMiD-sensitive phase of their disease. In addition, our data on the exposure to IMiDs before the acquisition of *CRBN* mutations indicated that the development of *CRBN* mutations might be correlated with long-term exposure to IMiDs, but this has to be taken with great caution because of the limited number of patients in this analysis. Regrettably, no prior samples were available from the other 3 patients with mutant *CRBN*, and larger studies on sequential assessments in patients under IMiD treatment are needed.

To further investigate the functional effect of these mutations on the response to lenalidomide, we introduced them into OCI-MY5 cells and confirmed that all 3 mutations caused *in vitro* IMiD resistance. These findings support a causal relationship between the appearance of these mutations and the lack of response to IMiDs in the patients. Tumor heterogeneity and the impact of subclonal somatic mutations on the response to targeted cancer therapies have been frequently discussed in relation to various cancers.⁵⁷ Of interest, in a recent publication, there

was evidence that low-frequency mutations in *KRAS* may cause resistance to anti-epidermal growth factor receptor therapy in colorectal cancer, even if mutant allele frequency was as low as 0.4% to 17%,⁵⁸ and similar reports were published for gefitinib resistance in lung cancer.^{59,60} The authors discuss potential explanations, including amplification of the gene locus and the possibility of parallel evolution of distinct resistance mechanisms within different subclones of a tumor. Whether such explanations might hold true in rMM remains to be addressed.

Including the mutation described above, we have detected 15 *CRBN* mutations in 9 MM patients thus far by M³P sequencing at the Mayo Clinic, all of the patients being clinically resistant to IMiD treatment.^{7,19} This includes an additional patient who was initially responsive to thalidomide and lenalidomide treatment, who acquired resistance to lenalidomide over the disease course, and who was finally unresponsive to pomalidomide treatment at the time of tumor sampling. In this patient, we detected a total of 6 mutations within *CRBN*: (p.Lys401Glu, 40% VR; p.His397Tyr, 6% VR; p.Pro352Ser, 2% VR; p.Ile314Ser, 11% VR; p.Leu308Phe, 5% VR; and p.Leu190Phe, 7% VR). Of note, all mutations but 1 were located within the thalidomide-binding domain, critical for the response to IMiDs. We had 2 prior samples available from earlier time points and, as with the 3 patients described above, we were unable to detect the mutations in *CRBN* when the patient was still sensitive to IMiD treatment.

In summary, our study supports the hypothesis that *CRBN* mutations predominantly, but not exclusively, occur in advanced MM.




Figure 4. CRBN mutations identified in our cohort confer lenalidomide resistance in OCI-MY5 cells. OCI-MY5 cells are resistant to IMiD treatment because of low CRBN expression levels. IMiD sensitivity can be restored by CRBN wt over-expression. (A) All 3 CRBN mutants failed to resensitize the cell line; thus, the mutations conferred IMiD resistance. (B) Protein expression by western blot.

These CRBN mutations are probably evoked by clonal selection under prolonged IMiD-based therapy, and their appearance probably contributes to IMiD-resistant MM disease. Clearly, the subclonal appearance of CRBN mutations in some patients requires further investigation. In addition, our study provides evidence of an altered mutational landscape in drug-resistant MM that presents most significantly with an increased number of mutations in the MAPK pathway. Whether these MAPK mutations are associated with resistance to IMiD treatment or are, more likely, positively selected by repeated drug exposures in advanced disease, remains to be determined.

Acknowledgments

This study was supported by research funding from Oncospire (A.K.S.), by Grant No. KO 4604/1-2 [705 136/807 015] from the Deutsche Forschungsgemeinschaft (K.M.K.), by a grant within the

Max-Eder Program of German Cancer Aid (Deutsche Krebshilfe) (M.S.R.), and by a research grant from Novartis GmbH (M.S.R.).

Authorship

Contribution: A.K.S., E.B., E.K.M., K.M.K., M.S.R., and P.L.B. designed the research; A.J., C.-X.S., J.X., K.M.K., L.B., M.A., N.H.H., P.J., and Y.-X.Z. performed experiments; A.K.S., E.B., E.K.M., K.M.K., M.S.R., N.H.H., R.A.S., and S.B. analyzed data; A.K.S., E.B., E.K.M., K.M.K., and M.S.R. wrote the manuscript; and E.K.M., M.M., J.H., and H.G. recruited patients and provided clinical information.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.S.R., 0000-0003-4181-6922.

Correspondence: A. Keith Stewart, Mayo Clinic in Arizona, 13400 E. Shea Blvd, CRB Room 1-001, Scottsdale, AZ 85259; e-mail: stewart.keith@mayo.edu.

References

- Walker BA, Boyle EM, Wardell CP, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. *J Clin Oncol*. 2015;33(33):3911-3920.
- Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014;5:2997.
- Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*. 2014;25(1):91-101.
- Lonial S, Yellapantula VD, Liang W, et al. Interim Analysis of the MMRF CoMMpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression [abstract]. *Blood*. 2014;124(21). Abstract 722.
- Keats JJ, Speyer G, Christophe L, et al. Identification of Initiating Trunk Mutations and

- Distinct Molecular Subtypes: An Interim Analysis of the MMRF CoMMpass Study [abstract]. *Blood*. 2015;126(23). Abstract 722.
6. Hofste op Bruinink D, Kortüm KM, van Duin M, et al. M³P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma [abstract]. *Blood*. 2015;126(23). Abstract 2984.
 7. Kortuem KM, Braggio E, Bruins L, et al. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. *Blood Cancer J*. 2016;6:e397.
 8. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. *Blood*. 2012;120(5):1060-1066.
 9. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. *Leukemia*. 2014;28(8):1705-1715.
 10. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. *Blood*. 2012;120(5):1067-1076.
 11. Kortüm KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK. Cereblon binding molecules in multiple myeloma. *Blood Rev*. 2015;29(5):329-334.
 12. Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. *Blood*. 2014;124(4):536-545.
 13. Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. *Leuk Res*. 2014;38(1):23-28.
 14. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood*. 2011;118(18):4771-4779.
 15. Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. *Br J Haematol*. 2013;161(5):695-700.
 16. Broyl A, Kuiper R, van Duin M, et al; Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. *Blood*. 2013;121(4):624-627.
 17. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science*. 2014;343(6168):301-305.
 18. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*. 2014;343(6168):305-309.
 19. Egan JB, Kortuem KM, Kurdoglu A, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. *Br J Haematol*. 2013;161(5):748-751.
 20. Donner KM, Hiltunen TP, Jänne OA, Sane T, Kontula K. Generalized glucocorticoid resistance caused by a novel two-nucleotide deletion in the hormone-binding domain of the glucocorticoid receptor gene NR3C1. *Eur J Endocrinol*. 2012;168(1):K9-K18.
 21. Shuqing L, Jianmin Y, Chongmei H, Hui C, Wang J. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. *Exp Hematol*. 2011;39(12):1117-1118.
 22. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. *Blood*. 2007;110(7):2242-2249.
 23. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014;370(24):2286-2294.
 24. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia*. 2006;20(9):1467-1473.
 25. Endris V, Penzel R, Warth A, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. *J Mol Diagn*. 2013;15(6):765-775.
 26. Kocher JP, Quest DJ, Duffy P, et al. The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation. *Bioinformatics*. 2014;30(13):1920-1922.
 27. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4(7):1073-1081.
 28. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet*. 2013; Chapter 7:Unit7 20.
 29. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-249.
 30. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PLoS One*. 2012;7(10):e46688.
 31. Rustad EH, Dai HY, Hov H, et al. BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. *Blood Cancer J*. 2015;5:e299.
 32. Andrulis M, Lehnert N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. *Cancer Discov*. 2013;3(8):862-869.
 33. Sen B, Peng S, Tang X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. *Sci Transl Med*. 2012;4(136):136ra70.
 34. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. *Cancer Discov*. 2014;4(9):1088-1101.
 35. Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. *Nat Genet*. 2015;47(10):1194-1199.
 36. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. *Nat Genet*. 2003;34(2):148-150.
 37. Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. *Cancer Res*. 2004;64(24):8816-8820.
 38. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. *Nat Struct Mol Biol*. 2014;21(9):803-809.
 39. Fischer ES, Böhm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. *Nature*. 2014;512(7512):49-53.
 40. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009;360(8):765-773.
 41. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010;28(14):2348-2355.
 42. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science*. 2013;340(6132):626-630.
 43. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science*. 2013;340(6132):622-626.
 44. Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. *Cancer Res*. 2013;73(16):5195-5205.
 45. Gust KM, McConkey DJ, Awrey S, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. *Mol Cancer Ther*. 2013;12(7):1245-1254.
 46. Gallo LH, Nelson KN, Meyer AN, Donoghue DJ. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. *Cytokine Growth Factor Rev*. 2015;26(4):425-449.
 47. Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. *Ann Oncol*. 2014;25(3):552-563.
 48. Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. *Eur J Haematol*. 2015;95(4):316-324.
 49. Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma. *Leukemia*. 2016;30(4):976-980.
 50. Steinbrunn T, Stühmer T, Sayehli C, Chatterjee M, Einsele H, Bargou RC. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. *Br J Haematol*. 2012;159(4):430-440.
 51. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. *Nat Genet*. 2006;38(3):294-296.
 52. Guan J, Gupta R, Filipp FV. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. *Sci Rep*. 2015;5:7857.
 53. Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape of juvenile myelomonocytic leukemia. *Nat Genet*. 2015;47(11):1326-1333.
 54. Prahallad A, Heynen GJ, Germano G, et al. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. *Cell Reports*. 2015;12(12):1978-1985.
 55. Grosskopf S, Eckert C, Arkona C, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. *ChemMedChem*. 2015;10(5):815-826.
 56. Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RA-Sopathies. *J Hum Genet*. 2016;61(1):33-39.
 57. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. *Nat Rev Clin Oncol*. 2016;13(6):335-347.
 58. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature*. 2012;486(7404):532-536.
 59. Jänne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. *Lung Cancer*. 2008;60(Suppl 2):S3-S9.
 60. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin Invest*. 2006;116(10):2695-2706.